Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer

Molecular Carcinogenesis

Volumn 55, Issue 9, 2016, Pages 1378-1386

  Fujii, Tomomi ^a   Shimada, Keiji ^a   Tatsumi, Yoshihiro ^a   Tanaka, Nobumichi ^a   Fujimoto, Kiyohide ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EMT; miR 331 3p; prostate cancer; syndecan 1; TGF

Indexed keywords

DESMOPLAKIN; DICER; MICRORNA; MICRORNA 331 3P; NERVE CELL ADHESION MOLECULE; NEUROPILIN 2; SMAD4 PROTEIN; SYNDECAN 1; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84984985036     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22381     Document Type: Article

References (45)

1. Bernfield M, Götte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68:729–777.
2. Shimada K, Nakamura M, De Velasco MA, et al. Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci. 2010; 101:155–160.
3. Lammoglia-Ordiales L, Toussaint-Caire S, Contreras-Barrera M, et al. Assessment of syndecan-1 (CD138) and Ki-67 expression for differentiating keratoacanthoma and squamous cell carcinoma. J Drugs Dermatol 2013; 12:e53–e58.
4. Shariat SF, Svatek RS, Kabbani W, et al. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int 2008; 101:232–237.
5. Shimada K, Nakamura M, Ishida E, et al. Prostate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer. Cancer Sci. 2008; 99:39–45.
6. Kumar A, Rao A, Bhavani S, Newberg JY, Murphy RF. Automated analysis of immunohistochemistry images identifies candidate location biomarkers for cancers. Proc Natl Acad Sci USA 2014; 111:18249–18254.
7. Tsaur I, Noack A, Makarevic J, et al. CCL2 chemokine as a potential biomarker for prostate cancer: A pilot study. Cancer Res Treat 2015; 47:306–312.
8. Toren P, Wong LM, Timilshina N, et al. Active surveillance in patients with a PSA >10ng/mL. Can Urol Assoc J 2014; 8:E702–E707.
9. Strand SH, Orntoft TF, Sorensen KD. Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci 2014; 15:16544–16576.
10. Konishi N, Nakamura M, Ishida E, et al. High expression of a new marker PCA-1 in human prostate carcinoma. Clin Cancer Res. 2005; 11:5090–5097.
11. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12:580–587.
12. Bartel DP. MicroRNAs genomics, biogenesis, mechanism, and function. Cell 2004; 116:281–297.
13. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115:787–798.
14. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev 2009; 10:704–714.
15. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Ann Rev Med 2009; 60:167–179.
16. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development 2005; 132:4653–4662.
17. Lin RJ, Lin YC, Yu AL. miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog 2010; 49:719–727.
18. Martin EC, Elliott S, Rhodes LV, et al. Preferential star strand biogenesis of pre-miR- 24–2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Mol Carcinog 2014; 53:38–48.
19. Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N. MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog 2014; 53:349–359.
20. Xu W, Ji J, Xu Y, et al. MicroRNA-191, by promoting the EMT and increasing CSC-like properties, is involved in neoplastic and metastatic properties of transformed human bronchial epithelial cells. Mol Carcinog 2015; 54 Suppl 1:E148–E161.
21. Paz EA, LaFleur B, Gerner EW. Polyamines are oncometabolites that regulate the LIN28/let-7 pathway in colorectal cancer cells. Mol Carcinog 2014; 53:E96–E106.
22. Ress AL, Stiegelbauer V, Winter E, et al. MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Mol Carcinog 2014. doi: 10.1002/mc.22218
23. Li C, Nguyen HT, Zhuang Y, et al. Post-transcriptional up-regulation of miR-21 by type I collagen. Mol Carcinog 2011; 50:563–570.
24. Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Konishi N. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci 2009; 100:1248–1254.
25. Shimada K, Anai S, Fujii T, Tanaka N, Fujimoto K, Konishi N. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells. J Pathol 2013; 231:495–504.
26. Fujii T, Shimada K, Tatsumi Y, Fujimoto K, Konishi N. Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. Biochem Biophys Res Commun 2015; 456:183–189.
27. Liu YN, Yin JJ, Abou-Kheir W, Sheppard-Tillman H, Martin P, Kelly K. MiR-1 and miR-200 inhibit EMT via slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene 2013; 32:296–306.
28. Coppola V, Musumeci M, Patrizii M, et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene 2013; 32:1843–1853.
29. Peng X, Guo W, Liu T, et al. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS ONE 2011; 6:e20341.
30. Zhu C, Li J, Cheng G, et al. MiR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem. 2013; 379:69–75.
31. Qu Y, Li WC, Hellem MR, et al. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer 2013; 133:544–555.
32. Kong D, Li Y, Wang Z, et al. MiR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009; 27:1712–1721.
33. Tucci P, Agostini M, Grespi F, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 2012; 109:15312–15317.
34. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13:97–110.
35. Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFbeta in cancer. FEBS Lett 2012; 586:1959–1970.
36. Liu XH, Sun M, Nie FQ, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer 2014; 13:92.
37. Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ. MiR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol 2014; 116:67–75.
38. Epis MR, Barker A, Giles KM, Beveridge DJ, Leedman PJ. The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem 2011; 286:41442–41454.
39. Chang RM, Yang H, Fang F, Xu JF, Yang LY. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology 2014; 60:1251–1263.
40. Goel HL, Mercurio AM. Enhancing integrin function by VEGF/neuropilin signaling: Implications for tumor biology. Cell Adhes Migr 2012; 6:554–560.
41. Nakayama K, Nakayama N, Davidson B, et al. BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 2006; 103:18739–18744.
42. Nishi T1, Maruyama R, Urano T, et al. Low expression of nucleus accumbens-associated protein 1 predicts poor prognosis for patients with pancreatic ductal adenocarcinoma. Pathol Int 2012; 62:802–810.
43. Erler P, Keutgen XM, Crowley MJ, et al. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer. Surgery 2014; 156:1342–1350.
44. Caffrey E, Ingoldsby H, Wall D, et al. Prognostic significance of deregulated dicer expression in breast cancer. PLoS ONE 2013; 8:83724.
45. Bian XJ, Zhang GM, Gu CY, et al. Down-regulation of Dicer and Ago2 is associated with cell proliferation and apoptosis in prostate cancer. Tumour Biol 2014; 35:11571–11578.